期刊
EXPERT REVIEW OF HEMATOLOGY
卷 8, 期 4, 页码 457-479出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2015.1041910
关键词
adverse events; bosutinib; chronic myeloid leukemia; dasatinib; imatinib; nilotinib; ponatinib; safety; tolerability; tyrosine kinase inhibitors
类别
资金
- Novartis
- Bristol-Myers Squibb
- Novartis Pharmaceuticals
Current treatment recommendations for chronic myeloid leukemia (CML) are guided by results from multiple clinical trials involving tyrosine kinase inhibitors that target BCR-ABL1. Consideration of the unique clinical benefits and potential risks associated with each tyrosine kinase inhibitor approved for the treatment of CML is crucial for physicians when recommending the most appropriate therapy for each patient. Monitoring for and prompt management of adverse events may increase adherence to therapy and optimize patient outcomes. Here we provide an overview of the efficacy and safety of tyrosine kinase inhibitors approved for the treatment of CML, as well as recommendations for the management of key adverse events reported with these agents in clinical trials involving patients with CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据